Atea Pharmaceuticals (AVIR) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 64.5% versus a loss of 13.9%. Atea Pharmaceuticals is the larger company by market cap ($413.1 million vs $395.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | KYTX |
|---|---|---|
| Share price | $5.15 | $6.39 |
| Market cap | $413.05M | $395.18M |
| 1-day change | -0.10% | +3.40% |
| YTD return | +44.26% | -34.26% |
| 1-year return | +64.54% | -13.93% |
| 5-year return | -86.89% | — |
| EPS (TTM) | $-2.09 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $13.67 |
| 52-week low | $2.87 | $5.96 |
| Distance from 52-week high | -20.16% | -53.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +82.91% | +375.74% |
| Average volume | 298.86K | 903.83K |
| Shares outstanding | 80.20M | 61.84M |
| Employees | 55 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed KYTX by 78.5 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
AVIR vs KYTX FAQ
Which is bigger, Atea Pharmaceuticals or Kyverna Therapeutics?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $413.05M compared with $395.18M for Kyverna Therapeutics (KYTX).
Which stock has performed better over the past year, AVIR or KYTX?
AVIR returned +64.54% over the past 12 months, compared with -13.93% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Kyverna Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Atea Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Kyverna Therapeutics.